Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-11-17 | Amended | $6,150,005 | $7 | Equity Only | 06c | SEC link |
| 2025-02-19 | Amended | $6,149,998 | $0 | Equity Only | 06b | SEC link |
| 2024-02-22 | Amended | $6,149,998 | $0 | Equity Only | 06b | SEC link |
| 2023-03-14 | New | $6,149,998 | $6,149,998 | Equity Only | 06b | SEC link |
| 2022-05-19 | Amended | $3,687,500 | $1,130,000 | Equity and Debt | 06c | SEC link |
| 2021-11-19 | Amended | $2,557,500 | $557,500 | Equity and Debt | 06c | SEC link |
| 2021-03-31 | Amended | $2,000,000 | $0 | Equity and Debt | 06c | SEC link |
| 2020-12-14 | Amended | $2,000,000 | $1,000,000 | Equity and Debt | 06c | SEC link |
| 2019-12-19 | Amended | $1,000,000 | $1,000,000 | Equity and Debt | 06c | SEC link |
| 2019-09-09 | New | Yet to Sell | $0 | Equity and Debt | 06c | SEC link |
| Name | Role |
|---|---|
| Sidney Hopps | Director, Executive |
| Brendan Kenny | Director |
| Gloria Olivier | Director |
| Gabriel Raviv | Director |
| G. Patrick Sage | Director |
| Patrick G. Sage, Ii | Director |
| G. Patrick Sage, Ii | Director |
| Richard Schuler | Director |
| Kenneth J. Templin | Executive |